[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Hospitalier Universitaire de Nice\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":545},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,165,0,25,[9,46,72,95,122,147,172,195,219,240,264,285,305,328,347,367,382,398,414,432,454,471,490,509,528],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100556299","presence-of-anti-rach-antibodies-and-neurocognitive-disorder-in-myasthenic-or-alzheimerss-patients-100556299",false,"NCT06523296","Presence of Anti-RACH Antibodies and Neurocognitive Disorder in Myasthenic or Alzheimers's Patients.","Study of the Relationship Between the Presence of Anti-AChR Antibodies in the Cerebrospinal Fluid and the Presence of Neurocognitive Disorder in Myasthenic and Alzheimers's Patients.","ARN-MA","Inclusion criteria\n\nFor patient with myasthenia :\n\n1. adult person,\n2. Diagnosis of anti-AChR positive autoimmune myasthenia gravis, confirmed by clinical and biological data, and categorized in class I to IV according to the Myasthenia Gravis Foundation of America (MGFA) classification,\n3. Mild or major neurocognitive disorder (DSM-5 criterion) having benefited from a diagnosis at the CMRR with CSF biomarker dosage and agreement to bio-collect residual CSF,\n4. Agreeing to sign the free and informed consent,\n5. Affiliate or beneficiary of a social security system.\n\nFor patient with Alzheimer Disease :\n\n1. adult person,\n2. Mild or major neurocognitive disorder (DSM-5 criterion) having benefited from a diagnosis at the CMRR with CSF biomarker dosage and agreement to bio-collect residual CSF,\n3. Neurocognitive disorder only linked to Alzheimer's disease (IWG-2 criterion): typical or atypical clinical form with biomarkers of Alzheimer's disease in the CSF;\n4. Agreeing to sign the free and informed consent,\n5. Affiliate or beneficiary of a social security system.\n\nFor healty control :\n\n1. absence of memory complaint,\n2. absence of neurocognitive disorder,\n3. Having agreed to carry out analyzes as part of research, on these CSF samples stored in the biobank of the Institute of Translational Neurology in Münster (Germany)\n\nExclusion Criteria:\n\nFor patient with myasthenia :\n\n1. Person who does not have sufficient command of the French language to understand, read and write, to take neuropsychological tests;\n2. Need to use the routine complementary CSF tube to carry out additional diagnostic explorations as part of routine care,\n3. Vulnerable people are defined in articles L1121-5 to -8 ( Pregnant women, parturients and breastfeeding mothers, persons deprived of their liberty by a judicial or administrative decision, persons hospitalized without consent under articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of article L. 1121-8, and persons admitted to a health or social establishment for purposes other than research\u002FAdults who are subject to a legal protection measure or who are unable to express their consent.),\n\nFor patient with Alzheimer Disease :\n\n1\\) vulnerable people are defined in articles L1121-5 to -8 ( Pregnant women, parturients and breastfeeding mothers, persons deprived of their liberty by a judicial or administrative decision, persons hospitalized without consent under articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of article L. 1121-8, and persons admitted to a health or social establishment for purposes other than research\u002FAdults who are subject to a legal protection measure or who are unable to express their consent.)","ALL","18 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of the study is to evaluate if there is a specific association between the presence of anti Rach antibodies in the CSF and the presence of a cogntive disorder in myasthenic patients. Moreover the investigator wants to study if there is a link between the presence of Anti RACH antibodies in myasthenia and Alzheimers's disease.\n\nFor that, the investigator will recruit myasthenic patient with cognitive disorder that has undergo a diagnostic process including lombar punction for memory trouble in Nice memory center as well as Alzheimer's patient having go through the same process.\n\nThe study will consist in one additionnal blood draw. Anti RACH antibodies will be analyzed in historical CSF stored in biocollection and serum collected for the study.\n\nLCS of healthy control will also be analyzed.",[28,29],"Alzheimer Disease","Myasthenia",[31,29,32,33],"Anti-RACH antibodies","Alzheimer's Disease","neurocognitve disorder","RECRUITING","2026-08-18",{"date":37,"type":38},"2026-08-19","ACTUAL",{"date":35,"type":38},{"date":41,"type":22},"2028-09-18",{"name":43,"class":44},"Centre Hospitalier Universitaire de Nice","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100651462","prevention-of-ischemia-in-aneurysmal-subarachnoid-hemorrhage-through-remote-ischemic-preconditioning-100651462","NCT07761520","Prevention of Ischemia in Aneurysmal Subarachnoid Hemorrhage Through Remote Ischemic Preconditioning","Remote Ischemic Preconditioning (RIPC) and Aneurysmal Subarachnoid Hemorrhage (SAH)","HMA","Inclusion Criteria:\n\n* Age over 18 years\n* Hospitalization for aneurysmal subarachnoid hemorrhage confirmed by CT scan and\u002For lumbar puncture\n* Confirmation of intracranial aneurysm by CT angiography and\u002For cerebral angiography\n* Written informed consent obtained from the patient or legal representative\n* Affiliation to a social security system\n\nExclusion Criteria:\n\n* Skin, orthopedic, or vascular conditions of the limbs contraindicating ischemic preconditioning (e.g., ulcers, fractures, deep vein thrombosis)\n* Pregnancy\n* Withdrawal of informed consent",{"count":55,"type":22},140,[25],"Aneurysmal subarachnoid hemorrhage (SAH) is a severe form of stroke caused by bleeding around the brain. Despite early treatment of the initial hemorrhage, many patients develop delayed cerebral ischemia several days later, which is a major cause of neurological disability, cognitive impairment, and mortality. Current preventive and therapeutic strategies are only partially effective, highlighting the need for new treatment approaches.\n\nThis study investigates a simple, non-invasive technique called remote ischemic preconditioning (RIPC). RIPC consists of brief, repeated cycles of limb ischemia and reperfusion induced by a blood pressure cuff. RIPC is thought to activate endogenous protective mechanisms that may improve the brain's tolerance to ischemia. Although beneficial effects have been reported in experimental models and cardiovascular diseases, its clinical efficacy in aneurysmal SAH remains uncertain.\n\nIn this randomized, controlled, single-blinded, multicenter study, adult patients admitted with aneyrysmal SAH will be randomly assigned to receive RIPC or a sham procedure. The RIPC group will undergo cycles of brief lower-limb ischemia using a pressure cuff, while the sham group will receive an identical procedure without inducing ischemia. Patients and neurologists assessing outcomes will remain blinded to group allocation.\n\nThe intervention will be performed every two days from day 2 to day 10 after hemorrhage. Neurological outcome will be assessed at 3 months using the modified Rankin Scale. Secondary outcomes include mortality at 3 months, long-term neurological and cognitive function outcomes at 12 months, and the incidence of adverse events related to the procedure.\n\nIf effective, RIPC could become a simple, low-cost, widely accessible method to reduce disability after SAH. The results may help improve future treatment strategies for this severe condition.",[59],"Aneurysmal Subarachnoid Hemorrhage",[61,62],"Aneurysmal Subarachnoid Hemorrhage (aSAH)","Remote Ischemic Preconditioning (RIPC)","NOT_YET_RECRUITING","2026-08-11",{"date":66,"type":38},"2026-08-12",{"date":68,"type":22},"2026-09",{"date":70,"type":22},"2029-09",{"name":43,"class":44},{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":92,"leadSponsor":94,"locationsCount":45},"100649935","comparison-of-different-peep-strategies-in-moderate-to-severe-ards-based-on-various-bedside-assessment-tools-100649935","NCT07741916","Comparison of Different PEEP Strategies in Moderate-to-Severe ARDS Based on Various Bedside Assessment Tools","Comparison of Different PEEP Strategies in Moderate-to-Severe Acute Respiratory Distress Syndrome (ARDS) Based on Various Bedside Assessment Tools","OPTI-PEEP","Inclusion Criteria:\n\n* Patients on invasive mechanical ventilation\n* With moderate-to-severe ARDS :\n\n  1. Bilateral findings on chest X-ray\n  2. PaO₂\u002FFiO₂ ratio \\\u003C200 with PEEP ≥+5 cmH₂O\n  3. No evidence of cardiogenic pulmonary overload\n* Patients without inspiratory effort (curare administration not required)\n* Patient already fitted with an esophageal pressure probe\n* Patient already fitted with a thoracic impedance belt\n* No objection from the patient or a family member to the processing of their clinical data\n\nExclusion Criteria:\n\n* Protected individuals, namely:\n\n  1. Individuals receiving enhanced protection, namely minors\n  2. Individuals deprived of their liberty by a judicial or administrative decision\n  3. Pregnant and breastfeeding women\n  4. Individuals residing in a health or social care facility\n  5. Adults under legal guardianship\n* Patients with a do-not-resuscitate order or a decision to limit care\n* Patients with a pacemaker or an implantable cardioverter-defibrillator\n* Acute cor pulmonale\n* Pneumothorax or ongoing pleural\u002Fthoracic drainage\n* Patients in the prone position\n* Hemodynamic instability\n\n  1. An increase of \\>30% in the norepinephrine dosage over the past 6 hours\n  2. Norepinephrine dosage \\> 0.5 µg\u002Fkg\u002Fmin\n* Patients on veno-venous ECMO",{"count":81,"type":22},45,[25],"Many patients admitted to the intensive care unit (ICU) for a severe lung disease called acute respiratory distress syndrome (ARDS) require mechanical ventilation and positive end-expiratory pressure (PEEP) to improve their oxygenation. Ventilator settings-and particularly the level of PEEP-are critical in the management of these patients. In fact, inappropriate ventilator settings can lead to a worsening of the patients' lung disease or compromise their hemodynamic status.\n\nPEEP is a pressure maintained by the ventilator during the patient's exhalation to keep the alveoli open throughout the respiratory cycle. When PEEP is increased, if many alveoli open, this is called alveolar recruitment, which is the expected beneficial effect. However, in some patients, increasing PEEP can cause already-open alveoli to become overdistended without opening new alveoli; this is known as pulmonary overdistension. This phenomenon of overdistension will worsen the patient's pulmonary condition and may also lead to hemodynamic deterioration. To date, numerous techniques have been proposed for determining the optimal PEP level (alveolar recruitment without pulmonary overdistension) in these patients, but none can be recommended as the gold standard. The objective of our study is therefore to compare the various existing methods for determining the optimal PEEP level, in order to determine whether these methods are interchangeable and which would be the best method to use to optimize the care of these patients.\n\nTo this end, the investigators plan to conduct a prospective, observational, multicenter study in the Intensive Care Units of the Nice University Hospital and the European Hospital of Marseille. Patients on mechanical ventilation for ARDS will be included in the study, and medical and laboratory data from the electronic medical records obtained during the various PEEP measurements to determine the optimal PEEP will be analyzed.",[85],"Acute Respiratory Distress Syndrome",[85,87],"positive end expiratory pression","2026-07-28",{"date":90,"type":38},"2026-08-03",{"date":68,"type":22},{"date":93,"type":22},"2030-01",{"name":43,"class":44},{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":18,"minAge":103,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":4},"100649330","healthy-aging-together---getting-to-know-you-better-healthy-aging-and-predictive-indicator-100649330","NCT07734246","Healthy Aging Together - \"Getting to Know You Better\": Healthy Aging and Predictive Indicator","BVE-HAPI","Inclusion Criteria:\n\n* Age 55 years or older\n* Affiliation with or beneficiary of a social security scheme\n* No objection to the study\n\nExclusion Criteria:\n\n* Persons protected by law, under guardianship or curatorship,\n* Persons deprived of liberty",true,"55 Years",{"count":105,"type":22},500,[25],"A key challenge lies in preventing the loss of autonomy and promoting healthy aging-a concept now widely addressed through multidimensional and multidisciplinary approaches, as evidenced by frailty models, comprehensive geriatric assessment practices, and the WHO's \"intrinsic capacity\" model. That said, there is a need to assess in greater detail the extent to which individual factors contribute to health trajectories and to move further by adopting a systemic approach that examines not only the relationships between variables but also their complex interactions. The aim of this study is to identify the multidimensional determinants (medical, physical, nutritional, sensory, psycho-cognitive, psychosocial, and socioeconomic) associated with the autonomy and quality of life of older adults and those who are aging.",[109],"Aging Disorder",[111,112,113],"healthy aging","autonomy","geriatric","2026-07-24",{"date":116,"type":38},"2026-07-29",{"date":118,"type":22},"2026-11",{"date":120,"type":22},"2029-03",{"name":43,"class":44},{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":129,"minAge":19,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":23,"phases":133,"briefSummary":134,"conditions":135,"keywords":138,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":45},"100625987","identify-a-specific-immune-profile-in-patients-with-chronic-pelvic-pain-resistant-to-first-line-treatments-by-measuring-th1-th2-th17-and-treg-cytokines-produced-after-non-specific-functional-cell-stimulation---immunocpp-100625987","NCT07429773","Identify a Specific Immune Profile in Patients With Chronic Pelvic Pain Resistant to First-line Treatments by Measuring Th1, Th2, Th17, and Treg Cytokines Produced After Non-specific Functional Cell Stimulation - ImmunoCPP","ImmunoCPP","Inclusion Criteria:\n\n1. Aged between 18 and 40;\n2. Under continuous hormone treatment for at least 6 months;\n3. Imaging less than 12 months old: either normal or showing endometriosis and\u002For adenomyosis lesions, excluding any other abnormalities that could explain the PCOS;\n4. Affiliation with the French Social Security system;\n5. Signature of informed consent.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women;\n2. Autoimmune disease;\n3. History of cancer within the last 5 years or currently undergoing treatment;\n4. Current infectious syndrome;\n5. Person under guardianship or conservatorship.","FEMALE","40 Years",{"count":132,"type":22},120,[25],"Chronic pelvic pain (CPP) affects more than one in four women. An immune imbalance in the Th1\u002FTh2 balance has been reported in multiple CPP situations, particularly in patients with endometriosis, but with mixed results. The use of a functional immune test, already validated in previous indications and particularly in infertility, could simulate an immune stimulation similar to that of painful attacks.",[136,137],"Endometriosis","Chronic Pelvic Pain Syndrome",[136,137,139],"women",{"date":141,"type":38},"2026-07-27",{"date":143,"type":38},"2026-04-14",{"date":145,"type":22},"2028-04",{"name":43,"class":44},{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":23,"phases":158,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":167,"startDateStruct":168,"completionDateStruct":169,"leadSponsor":171,"locationsCount":45},"100598663","phase-4-effect-of-empagliflozin-in-patients-with-egfr-between-10-and-20-mlmin173m2-100598663","NCT07074418","Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml\u002FMin\u002F1.73m2","Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml\u002FMin\u002F1.73m2 - EMPA [10-20]","EMPA[10-20]","Inclusion Criteria:\n\n* type 2 diabetics,\n* age between 18 and 80 years,\n* RAS blockade at maximal tolerated dosage for 1 month,\n* eGFR (CKD-EPI) between 10 and 20 ml\u002Fmin\u002F1.73m2,\n* UACR \\> 300mg\u002Fg creatinine and UPCR \\> 500mg\u002Fg creatinine,\n* office systolic blood pressure \\> 110 mmHg,\n* stable dosage of antihypertensive drugs and diuretics for 1 month.\n\nExclusion Criteria:\n\n* any medical condition that, in the opinion of the investigator makes the participant not suitable for inclusion,\n* history of ketoacidosis in the past while on empagliflozin or any other SGLT2i class drugs,\n* participation in another clinical study with an investigational medicinal product (IMP) administered during the month before screening,\n* known hypersensitivity or intolerance to empagliflozin or any of the excipients of the product,\n* judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements,\n* no social insurance,\n* unwilling to give informed consent, vulnerable persons (minors, adults under guardianship or trusteeship, pregnant women, persons deprived of their liberty, persons unable to speak French).","80 Years",{"count":157,"type":22},34,[159],"PHASE4","The proximal tubule remains the main site for sodium reabsorption in patients with advanced renal failure. The investigators therefore hypothesize that SGLT2i should still exert a significant natriuretic effect in patients with eGFR below 20 ml\u002Fmin\u002F1.73m2, and therefore should still decrease proteinuria with a potential renal protective effect.",[162],"Chronic Kidney Diseases",[164,165,166],"Chronic Kidney Disease","Nephrology","eGFR",{"date":141,"type":38},{"date":68,"type":22},{"date":170,"type":22},"2028-05",{"name":43,"class":44},{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":12,"sex":18,"minAge":180,"maxAge":19,"enrollmentInfo":181,"targetDuration":4,"studyType":23,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":45},"100539203","inorganic-pyrophosphate-homeostasis-ppi-in-pediatric-chronic-kidney-disease-100539203","NCT06300788","Inorganic Pyrophosphate Homeostasis (PPi) in Pediatric Chronic Kidney Disease","Inorganic Pyrophosphate Homeostasis (PPi) in Pediatric Chronic Kidney Disease - PPi-DIA","PPi-DIA","Inclusion Criteria:\n\nAll groups :\n\n* Minor patients (\\\u003C18 years)\n* Patients of both sexes\n* Informed patients and parents who have signed the informed consent form\n* Patients affiliated to social security\n\nControl group :\n\n\\- Patients with no particular pathology undergoing surgery and receiving a preoperative check-up\n\nCKD groups :\n\n* Patients on dialysis for more than 3 months, regardless of technique\n* Kidney transplant patients\n* Patients with CKD, whatever the cause\n\nExclusion Criteria:\n\n* Progressive cancer or kidney disease\n* Treatments that may modify PPi concentration (e.g. bisphosphonates)","0 Years",{"count":182,"type":22},60,[25],"The investigator aim to identify the role of inorganic pyrophosphate and other anti-calcifying molecules in vascular disease in children with chronic kidney disease, with a view to developing therapeutic approaches aimed at limiting the onset of vasculopathy.",[186],"Pyrophosphate, Fetuin A, IL1, IL6, TNFalpha, Control",[188],"Pyrophosphate",{"date":141,"type":38},{"date":191,"type":38},"2024-05-27",{"date":193,"type":22},"2027-11-27",{"name":43,"class":44},{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":45},"100648766","single-center-study-evaluating-the-impact-of-age-on-the-diagnostic-performance-of-the-sural-to-radial-sensory-amplitude-ratio-in-length-dependent-and-non-length-dependent-peripheral-polyneuropathies-100648766","NCT07725120","Single-Center Study Evaluating the Impact of Age on the Diagnostic Performance of the Sural-to-Radial Sensory Amplitude Ratio in Length-Dependent and Non-Length-Dependent Peripheral Polyneuropathies","Retrospective Single-Center Study Evaluating the Impact of Age on the Diagnostic Performance of the Sural-to-Radial Sensory Amplitude Ratio in Length-Dependent and Non-Length-Dependent Peripheral Polyneuropathies","ASPIRE","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Diagnosis of peripheral sensory polyneuropathy.\n* Classification as length-dependent (LDN) or non-length-dependent (NLDN) based on clinical and electrophysiological findings.\n* Available nerve conduction study including sural and radial sensory nerve amplitudes allowing calculation of the SRAR.\n* Evaluated at the Peripheral Neuromuscular Rare Disease Reference Center, Nice University Hospital, between January 2013 and July 2026.\n\nExclusion Criteria:\n\n* Missing or incomplete clinical or electrophysiological data preventing SRAR calculation.\n* Unclassifiable neuropathy phenotype.\n* Technical factors affecting the reliability of nerve conduction studies.","90 Years",{"count":205,"type":22},180,"OBSERVATIONAL","This retrospective single-center observational study will evaluate the impact of age on the diagnostic performance of the sural-to-radial sensory nerve amplitude ratio (SRAR) in patients with length-dependent and non-length-dependent peripheral sensory polyneuropathies. Clinical and electrophysiological data collected during routine care between January 2013 and July 2026 will be analyzed. Diagnostic performance will be assessed using receiver operating characteristic (ROC) curve analysis across predefined age groups to determine whether age-adjusted SRAR thresholds improve the differentiation between the two polyneuropathy phenotypes.",[209,210,211],"Polyneuropathies","Electromyography","Diagnostic Techniques","2026-07-21",{"date":114,"type":38},{"date":215,"type":22},"2026-09-01",{"date":217,"type":22},"2026-12-31",{"name":43,"class":44},{"id":220,"slug":221,"hasResults":12,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":203,"enrollmentInfo":227,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":228,"conditions":229,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":237,"leadSponsor":239,"locationsCount":4},"100648330","ultrasound-driven-stratification-in-cidp-100648330","NCT07719153","Ultrasound-driven Stratification in CIDP","Ultrasound-driven Stratification in CIDP: A Prospective Observational Study Integrating Imaging and Circulating Biomarkers","TAILOR-CIDP","Inclusion Criteria:\n\n* Male or female aged 18 years or older.\n* Diagnosis of CIDP according to the 2021 EAN\u002FPNS criteria; eligible phenotypes include typical CIDP, asymmetric CIDP (MADSAM\u002FLewis-Sumner syndrome), and pure motor CIDP. Pure sensory CIDP is excluded.\n* Ability to undergo protocol assessments, including clinical evaluation, electrophysiological studies, nerve ultrasound, and blood sampling.\n* Ability to provide written informed consent.\n* Affiliation with a health insurance system or equivalent.\n\nGroup 1-specific criteria:\n\n* Newly diagnosed CIDP.\n* No previous immunomodulatory treatment for CIDP before baseline study assessment.\n* Planned initiation of IVIg according to standard clinical practice.\n\nGroup 2-specific criteria:\n\n* Established CIDP with persistent clinically relevant disability.\n* Documented inadequate, partial, transient, or absent response despite adequate prior therapy, according to the final refractory disease definition.\n* Stable treatment exposure before inclusion according to the final protocol.\n\nExclusion Criteria:\n\n* Pure sensory CIDP.\n* Alternative cause of neuropathy, including hereditary, metabolic, toxic, or other acquired neuropathies judged to better explain the clinical picture.\n* Motor neuron disease, myopathy, neuromuscular junction disorder, or another neurological or neuromuscular condition interfering with clinical, electrophysiological, or ultrasound interpretation.\n* CIDP mimic or alternative diagnosis.\n* Active infection likely to influence study assessments.\n* Active malignancy or other major systemic condition likely to confound biomarker interpretation.\n* Concomitant autoimmune or inflammatory disease likely to materially influence cytokine or complement measurements.\n* Severe psychiatric or cognitive disorder interfering with participation.\n* Participation in another interventional trial when incompatible with the present protocol.\n* Inability or unwillingness to comply with study procedures.",{"count":21,"type":22},"Chronic inflammatory demyelinating polyradiculoneuritis (CIDP) is a rare autoimmune neuropathy characterized by significant clinical and therapeutic heterogeneity. Despite the availability of effective treatments, the response to intravenous immunoglobulins remains highly variable, and there are currently no validated biomarkers that can predict this response.\n\nAt the same time, high-resolution nerve ultrasound now makes it possible to identify different morphological profiles that may reflect distinct pathophysiological mechanisms.\n\nThis prospective, observational, single-center study, conducted at the Nice University Hospital, aims to determine whether nerve ultrasound profiles are associated with therapeutic response, clinical severity, and various biomarkers in the blood and cerebrospinal fluid. It includes two predefined cohorts: 20 patients with newly diagnosed PIDC, enrolled before the initiation of immunomodulatory treatment (Group 1), and 10 patients with refractory PIDC and clinically significant disability despite adequate prior treatment (Group 2). The ultimate goal is to develop a stratification strategy that will enable more personalized care for patients with PIDC.",[230,231,232],"CIDP","Chronic Inflammation","Demyelinating Polyneuropathy","2026-07-17",{"date":235,"type":38},"2026-07-22",{"date":215,"type":22},{"date":238,"type":22},"2029-09-30",{"name":43,"class":44},{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":18,"minAge":247,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":23,"phases":250,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":260,"leadSponsor":262,"locationsCount":263},"100647055","treatment-of-dysphagia-in-patients-with-dystrophic-epidermolysis-bullosa-with-budesonide-a-retrospective-bicentric-study-nice---paris-st-louis--necker-ebude-study-100647055","NCT07684105","Treatment of Dysphagia in Patients With Dystrophic Epidermolysis Bullosa With Budesonide: a Retrospective Bicentric Study Nice - Paris St Louis \u002F Necker (EBUDE Study)","EBUDE","Inclusion Criteria:\n\nPatients of both sexes, of any age, with EBD in dominant or recessive form, treated for at least one month with budesonide for dysphagia resistant to usual treatments.\n\nA description of the clinical form must be available in the file. The patient must assess the benefit of treatment at 1 and\u002For 3 months of Budesonide.\n\nPatients must be affiliated with social security. For adults, consent of non-opposition is required, and for minors, non-opposition from one of the parents or the person holding parental authority must be collected.\n\nExclusion Criteria:\n\nNo precise clinical or biological diagnosis. Treatment with Budesonide \\\u003C 1 month. No evaluation criteria in the file \u002F Objection to the use of data (withdrawal of non-opposition)","1 Year",{"count":249,"type":22},15,[25],"Budesonide is an anti-inflammatory medication that works by decreasing the immune system's overreaction. In the treatment of eosinophilic esophagitis, especially with Jorveza or a preparation made in a pharmacy, it reduces the production of substances responsible for inflammation in the esophagus. This action reduces the accumulation of certain inflammatory cells (eosinophils) and thus improves the symptoms and lesions of the esophagus.\n\nDystrophic epidermolysis bullosa (EBD) is a rare genetic disease that makes the skin and mucous membranes very fragile. Blisters, sores and wounds can appear as a result of even minor trauma. Scarring is often abnormal and can cause tissue to shrink or shrink.\n\nTo date, only two studies involving a total of eight children with EBD have evaluated a budesonide-based preparation. The results show an improvement in swallowing difficulties (dysphagia) as well as good tolerance of the treatment. However, there are currently no published data regarding the use of Jorveza in the form of an orally disintegrating tablet in adults with EBD.\n\nThrough the follow-up of patients treated at the MAGEC reference center, specialized in rare genetic diseases of the skin and mucous membranes, we aim to evaluate the interest and effects of budesonide treatment in individuals with EBD presenting with dysphagia.",[253,254,255],"Recessive Dystrophic Epidermolysis Bullosa","Dysphagia","Esophageal Stenosis","2026-07-01",{"date":258,"type":38},"2026-07-06",{"date":256,"type":22},{"date":261,"type":22},"2027-06-30",{"name":43,"class":44},3,{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":45},"100646563","three-ct-signs-of-nerve-root-suffering-in-low-back-sciatica-a-study-of-their-frequency-in-patients-referred-for-ct-guided-nerve-root-infiltration-100646563","NCT07690449","Three CT Signs of Nerve-root Suffering in Low-back Sciatica: a Study of Their Frequency in Patients Referred for CT-guided Nerve-root Infiltration.","Prevalence of Three CT Signs of Nerve-root Suffering (Root Size Asymmetry\u002FHypertrophy, Peri-radicular Infiltration, Spontaneous Hyperdensity) in Patients With Low-back Sciatica Referred for CT-guided Foraminal Infiltration: a Single-centre Retrospective Study (Nice University Hospital - Pasteur 2).","Inclusion Criteria:\n\n* Adult (\\>= 18 years)\n* Low-back sciatica \u002F radicular pain with a systematized distribution\n* Referred for CT-guided foraminal or peri-radicular infiltration at Pasteur 2 Hospital (Nice) between 30 Jan 2024 and 11 Jul 2024.\n* Available and interpretable pre-infiltration planning CT\n\nExclusion Criteria:\n\n* Planning CT missing or not interpretable\n* Missing data on the three studied signs\n* Radicular pain of tumoral, infectious or recent traumatic origin\n* Spinal history precluding analysis of the studied root",{"count":272,"type":22},400,"Retrospective, observational, single-centre study conducted at Nice University Hospital (Pasteur 2), Department of Diagnostic and Interventional Radiology. Objective: to assess the prevalence of three CT signs sought next to the clinically suspected nerve root in patients with low-back sciatica referred for CT-guided foraminal\u002Fperi-radicular infiltration: (1) nerve-root size asymmetry\u002Fhypertrophy, (2) peri-radicular infiltration, and (3) spontaneous root hyperdensity. Hypothesis: these signs are associated with the suffering nerve root responsible for the clinical presentation. Pre-infiltration planning CT scans (period 30 Jan 2024 - 11 Jul 2024) are reviewed by the operating radiologists (4th-, 5th- and 6th-year residents). Target enrollment: 400 patients. Data analysed to date: 104 patients \u002F 105 infiltrations. Preliminary prevalence: root asymmetry\u002Fhypertrophy 45.5%; peri-radicular infiltration 50.5%; spontaneous hyperdensity 23.8%; at least 2 of 3 signs 38.6%; all 3 signs 16.8%. Mean age 65 years (range 25-93); approximately 62 women \u002F 42 men; predominant levels L4-L5 and L5-S1.",[275,276,277],"Sciatica","Lumbosacral Radiculopathy","Low Back Pain",{"date":279,"type":38},"2026-07-08",{"date":281,"type":38},"2024-01-30",{"date":283,"type":22},"2026-10-01",{"name":43,"class":44},{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":23,"phases":294,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":45},"100633817","assessment-of-intra-abdominal-pressure-during-the-perioperative-period-of-hernia-repair-100633817","NCT07531615","Assessment of Intra-abdominal Pressure During the Perioperative Period of Hernia Repair","PRESSEVENT","Inclusion Criteria:\n\n* Midline incisional hernias with a hernia defect width between 4 and 10 cm in the transverse axis, corresponding to W2 according to the EHS classification\n* M2, M3, and M4 locations according to the EHS classification (i.e., hernia defects located from 3 cm below the xiphoid process to 3 cm above the upper border of the pubic symphysis)\n* Patients scheduled for elective open midline incisional hernia repair with retromuscular mesh placement\n* Provision of written informed consent\n* Affiliation with a national health insurance system\n\nExclusion Criteria:\n\n* Other types of incisional hernia\n* Minimally invasive surgery (laparoscopic or robotic approach)\n* Patients under legal protection (guardianship or curatorship), or patients unable to participate in a clinical study in accordance with Article L.1121-16 of the French Public Health Code\n* Pregnant or breastfeeding women of childbearing age",{"count":293,"type":22},10,[25],"Thousands of patients worldwide undergo abdominal surgery every day; 2-11% of laparotomies will progress to an incisional hernia, particularly midline laparotomies, which are associated with higher hernia rates, reaching up to 70% in obese patients (1,2). Long-term recurrence after incisional hernia repair is close to 30% after primary repair and may increase to 70% in cases of iterative (redo) surgery (3).\n\nThe main risk factors for incisional hernia formation or recurrence include surgical site infection, surgical technique, respiratory insufficiency (COPD), as well as overweight and obesity, the prevalence of which is rapidly increasing.\n\nMidline incisional hernias are the most frequent and represent a significant public health issue.\n\nIn abdominal wall surgery, some teams perform so-called tension-free repairs, whereas others favor repairs under tension. The tension-free concept may be associated with a lower recurrence rate. However, this intuitive concept has never been mechanically defined, using perioperative pressure measurements or surface tension assessment. Few studies have investigated abdominal pressure and muscle tension measurements in relation to abdominal wall surgery.\n\nThe aim of this study is to evaluate a protocol for measuring abdominal pressures during open repair of midline incisional hernia.",[297],"Hernia Incisional",{"date":299,"type":38},"2026-07-02",{"date":301,"type":22},"2026-07-30",{"date":303,"type":22},"2028-08-01",{"name":43,"class":44},{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":315,"conditions":316,"keywords":318,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":324,"leadSponsor":326,"locationsCount":327},"100645049","sexual-and-urinary-dysfunctions-in-generalized-myasthenia-100645049","NCT07677852","Sexual and Urinary Dysfunctions in Generalized Myasthenia","Sexual and Urinary Dysfunctions in Generalized Myasthenia: Impact on Quality of Life - the MYAOUS Study","MYAOUS","Inclusion Criteria:\n\n1. Minimum age of 18 years at the time the informed consent form is obtained.\n2. Confirmed diagnosis of generalized autoimmune myasthenia gravis, including at least two of the following:\n\n   1. Typical clinical features assessed by a physician specializing in myasthenia gravis\n   2. A decrease of ≥ 10% during repeated nerve stimulation (3-5 Hz) or increased irregularity on a single-fiber electromyogram\n   3. A positive edrophonium test or response to anticholinesterase agents\n   4. Serum anti-AChR or anti-MuSK antibodies.\n3. Enrolled in or covered by a social security program in accordance with current regulations governing research involving human subjects.\n\nExclusion Criteria:\n\n1. Pregnant (at the time of enrollment)\n2. Postpartum \\\u003C 6 months\n3. Severe cognitive impairment or under legal guardianship, making it impossible to understand or complete self-administered questionnaires.",{"count":314,"type":22},150,"Myasthenia gravis is an autoimmune disease caused by specific autoantibodies that disrupt the function of the neuromuscular junction. It manifests as excessive fatigue of the skeletal muscles during physical exertion and affects 15,000 people in France. Initial symptoms are most often ocular (ptosis, diplopia) but can later spread throughout the body, potentially leading in some cases to respiratory failure and\u002For swallowing difficulties (myasthenic crisis) or even death. This condition is currently being managed more effectively through treatment, and the invisible symptoms (sexual dysfunction, sphincter dysfunction, psychological impact, etc.) may ultimately be more debilitating than the initial symptoms, which are often controlled by maintenance and\u002For symptomatic treatments. The impact of myasthenia gravis on intimate life remains a taboo subject and is poorly understood by both the medical community and patients. In the literature, only a single article from 2021 addresses sexual dysfunction in patients with myasthenia gravis. Urinary disorders in myasthenia gravis are frequently reported but have also been little studied.\n\nA national survey, conducted using an online questionnaire distributed by patient associations, shed light on the disease's impact on patients' intimate lives. In this study of 190 patients, 46 of them responded to the question about sexual function, and one in two patients reported sexual complaints; in 46% of cases, this disorder significantly impacted the patients' daily lives. In particular, a decrease in the frequency of sexual intercourse with a partner was noted in 55% of cases, as well as a decrease in sexual desire in 51% of cases.\n\nSexual dysfunction is very common and underreported in many chronic neurological diseases. The Sexual Complaints Screener (SCS W\u002FM) questionnaires for women and men in English have very recently been validated in French (Questionnaires de Plaintes Sexuelles, QPS F\u002FH).\n\nIt now have a 10-item self-administered questionnaire that assesses the full range of sexual disorders and their impact.\n\nIn conclusion, while the visible symptoms of myasthenia gravis are widely recognized, the invisible symptoms-such as genitourinary and sphincter disorders-remain largely unrecognized and underdiagnosed. It is therefore essential to conduct systematic screening in order to best guide our patients and thereby improve their quality of life.",[317],"Myasthenia Gravis (MG)",[319,320],"genitourinary and sphincter disorders","Myasthenia gravis","2026-06-26",{"date":256,"type":38},{"date":301,"type":22},{"date":325,"type":22},"2030-07-30",{"name":43,"class":44},2,{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":336,"conditions":337,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":45},"100532738","study-of-the-location-of-motor-cortical-stimulation-electrodes-in-chronic-neuropathic-refractory-patients-100532738","NCT06216717","Study of the Location of Motor Cortical Stimulation Electrodes in Chronic Neuropathic Refractory Patients","Inclusion Criteria\n\n* adults\n* patient implanted with a motor cortical stimulation system for chronic neuropathic refractory pain,\n* patient with available postoperative scanner\n\nExclusion Criteria: None",{"count":335,"type":22},100,"Cortical stimulation has been used since 1991 to treat neuropathic pain. However, the underlying mechanisms are still incompletely understood and under-studied. In this protocol, the investigators aim to study the myeloarchitectonic and functional characteristics of areas activated by cortical epidural electrodes and to determine their relation to therapy response in chronic neuropathic refractory pain patients.",[338],"Neuropathic Pain","2026-06-25",{"date":341,"type":38},"2026-06-29",{"date":343,"type":38},"2023-11-13",{"date":345,"type":22},"2027-06-25",{"name":43,"class":44},{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":18,"minAge":130,"maxAge":355,"enrollmentInfo":356,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":358,"conditions":359,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":361,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":45},"100512709","characteristics-of-hoffa-adipose-tissue-and-intramuscular-adipose-tissue-in-the-quadriceps-muscle-100512709","NCT05955976","Characteristics of Hoffa Adipose Tissue and Intramuscular Adipose Tissue in the Quadriceps Muscle","Study to Compare the Characteristics of Hoffa Adipose Tissue and Intramuscular Adipose Tissue in the Quadriceps Muscle","ADIPENIGME","Inclusion Criteria:\n\n* Adult patient, aged between 40 and 85 years\n* Patient having a confirmed diagnosis of knee ostheoarthritis\n* Patient undergoing a surgery for a total knee prosthesis for knee ostheoarthritis\n\nExclusion Criteria:\n\n\\-","85 Years",{"count":357,"type":22},20,"Over the last few years, it has been suggested that Knee Ostheoarthritis (KOA) incidence and progression could potentially be related to skeletal muscle characteristics. In particular, weakness of the quadriceps muscle would be a key determinant of KOA. However the mechanisms underpinning the influence of skeletal muscle in the pathophysiology of ostheoarthritis (OA) are poorly understood.\n\nCrosstalk between skeletal muscle and structures around and in the joint is of interest. In physical deconditioning and aging, it has been reported that skeletal muscle can be replaced by adipose tissue. Several factors involved in the development of OA but also of adipose tissue may be involved in these muscular changes. Of interest, in patients with KOA, quadriceps weakness is an ubiquitous clinical finding. Infiltration of adipose tissue in skeletal muscle has been shown to affect muscle strength and mobility and be linked to cartilage volume loss and the occurrence\u002Fprogression of KOA.\n\nThe main objective of this study is to compare the characteristics of the Hoffa tissus and the intamuscular fat (IMF) tissus in the quadriceps muscle in patients with gonarthrosis requiring total knee prosthesis.\n\nThis is a single-centre study based on a collection of surgical waste and is categorized as Research Not Involving Human subjects.",[360],"Osteo Arthritis Knee",{"date":341,"type":38},{"date":363,"type":38},"2023-07-20",{"date":365,"type":22},"2027-06-20",{"name":43,"class":44},{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":374,"conditions":375,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":377,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":381,"locationsCount":45},"100507393","prediction-of-the-spontaneous-breathing-test-success-using-biosignal-and-biomarker-in-critical-care-unit-by-a-machine-learning-approach-100507393","NCT05886803","Prediction of the Spontaneous Breathing Test Success Using Biosignal and Biomarker in Critical Care Unit by a Machine Learning Approach","Inclusion Criteria:\n\n* Computerized health report (CHR)\n* Spontaneous breathing test should have been performed\n\nExclusion Criteria:\n\n* Spontaneous breathing test has not been performed,\n* Biosignal (cardiac, respiratory) are not registered in the CHR\n* Patient died before the spontaneous breathing test\n* Opposition to the study has been expressed.",{"count":105,"type":22},"Context:\n\nSeveral authors have been interested in applying Artificial Intelligence (AI) to medicine, using various Machine Learning (ML) techniques: managing septic shock, predicting renal failure... \\[1, 2\\] AI has an important place in decision support for clinicians \\[3\\]. The weaning period is a really important time in the management of a patient on mechanical ventilation and can take up to half of the time spent in intensive care unit. The first weaning attempt is unsuccessful in 20% of patients However, mortality can be as high as 38% in patients with the most difficult weaning \\[4\\]. Only a few studies have looked at the application of machine learning in this area, and only one has looked at the use of biosignals (cardiac rate, ECG, ventilatory parameters…) \\[5-7\\]. To improve morbidity, mortality and reduce length of stay, it is essential to be able to predict the success of the spontaneous breathing test and extubation.\n\nInvestigators propose to develop a predictive algorithm for the success of a ventilatory weaning test based on biosignal records and others features.\n\nMethods:\n\nIt is a critical care, oligo-centric and retrospective study the investigators included biosignal variables extracted from the electronic medical record, such as respiratory (RR, minute volume...), cardiac (systolic pressure, heart rate...), ventilator parameters and other discrete variables (age, comorbidity...). Most biosignal variables are minute-by-minute records. Recording starts 48 hours before the test and stops at the start of the weaning test. The investigators extracted features from these records, combined them with other biomarkers, and applied several machine learning algorithms: Logistic Regression, Random Forest Classifier, Support Vector Classifier (SVC), XGBoost, and Light Gradient Boosting Method (LGBM)…",[376],"Weaning From Mechanical Ventilation in Care Unit",{"date":341,"type":38},{"date":379,"type":38},"2023-01-01",{"date":345,"type":22},{"name":43,"class":44},{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":203,"enrollmentInfo":389,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":390,"conditions":391,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":393,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":397,"locationsCount":45},"100486142","study-of-the-metabolism-in-the-lymphatic-niche-of-cll-100486142","NCT05610228","Study of the Metabolism in the Lymphatic Niche of CLL","Study of the Metabolic Reprogramming of CLL Cells in Ex-vivo Models of the Lymphatic Niche","Inclusion Criteria:\n\n* Patients for whom the diagnosis of CLL has been established cytologically and phenotypically (Matutes score)\n* Patients over 18 years old\n* Patients who have signed the non-objection form\n* Untreated patients\n\nExclusion Criteria:\n\n* Patient with a solid cancer that is progressive or in remission for less than 3 years\n* HIV positive patients\n* Patients with chronic active hepatitis B or C\n* History of allogeneic transplant",{"count":21,"type":22},"Chronic lymphoid leukemia (CLL) is the most common adult leukemia that is characterized by a malignant monoclonal accumulation of tumoral and quiescent B cells in the peripheral blood. In advanced stages of the disease (Binet stage C), this population invades the bone marrow (BM) and proliferate into the lymphoid organs that results in widespread adenopathy. Richter's transformation is a most aggressive serious complication of CLL (transformation of the disease into an aggressive lymphoma) detected based on TEP\u002FCT (Positron Emission Tomography\u002F computerized tomography) that shows highly derived glucose consumption by cancer cells. Clinical data from CLL patients with disease acutisation showed hypermetabolic lymphadenopathy with high standardized uptake value (SUV) whereas there is low grade tracer uptake into BM. We supposed that the tumor microenvironment of the lymphatic niche promotes the proliferation and glycolytic activity of CLL cells which become particularly resistant to treatment. The development of an ex-vivo tumor model that reproduces the microenvironment of the lymph node niche appears essential to identify and validate new therapeutic targets because despite the therapeutic arsenal available some patients still relapse or are refractory to treatment. Our objectives are to i \u002F Characterize this niche of resistance by the development of an ex-vivo tumor model and ii \u002F Evaluate in-vitro the effectiveness of the association of current treatments (RFC, Ibrutinib or Venetoclax) with anti-metabolic therapies (inhibitors of glycolysis) Our lab is developing an ex-vivo models of the lymphatic niche in CLL based on co-cultures of leukemic cells from patients stimulated with CpG ODN and IL2 with primary human lymphatic fibroblasts (HLF) (EC 12PP15). This co-culture has never been described in the literature and allows us to study the lymphatic niche of CLL patients. Lymph node (LN) exploration in CLL requires invasive access and does not bring any additional information in initial diagnosis. Then, we validated our co-culture model using complementary approaches: increased viability, proliferation, and resistance to Ibrutinib, associated with increased production of anti-apoptotic proteins such as MCL1 and BCL2 after 48 hours of co-culture. Secondly, we studied the metabolism in this resistance niche. We find an increased production of lactate and an acute consumption of glucose, associated with a strong metabolic activation detected by SEAHORSE and by the production of glycolysis enzymes such as hexokinase 2. Our study constitutes an original project because it characterized the energy metabolism of the CLL lymphatic niche by developing an original ex-vivo model and enhanced our understanding of the contribution of the specific microenvironment in the dissociation of metabolic activity using SUV max in BM and lymphatic niche. Anti-metabolic therapies are efficient on co-culture CLL cells and could be an alternative for refractory or relapsed patients under current treatment.",[392],"CLL",{"date":341,"type":38},{"date":395,"type":38},"2018-11-07",{"date":345,"type":22},{"name":43,"class":44},{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":18,"minAge":130,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":406,"conditions":407,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":409,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":413,"locationsCount":45},"100484867","thromboxane-a2-and-osteoarthritis-100484867","NCT05593640","Thromboxane A2 and Osteoarthritis","Throboxane Effect on Chondrocytes; Role in Osteoarthritis","Inclusion Criteria:\n\n* presence of knee osteoarthritis with effusion, , no inflammatory disease\n\nExclusion Criteria:\n\n* anticoagulant treatment\n* inflammatory disease",{"count":357,"type":22},"TXA2 inhibits the expression of the primary marker of thermogenesis (UCP1) while prostacyclin (PGI2), another metabolite derived from arachidonic acid, enhances its expression. Given the close relationship between the adipocyte and the chondrocyte, the study team hypothesises that thromboxane A2 controls chondrocyte formation and function and thus cartilage homeostasis. The study objectives are: i) to analyse the role of TXA2 on chondrocyte differentiation in vitro, ii) to determine the association between circulating and tissue TXA2 levels in a rat model of osteoarthritis, and iii) to correlate circulating and synovial fluid levels of TXA2 with the development of osteoarthritis in a small human cohort. The proposed research aims to better understand the mechanisms underlying the role of lipid metabolites in chondrocyte formation and function, paving the way for the development of nutritional and pharmacological therapies to combat OA and associated metabolic disorders.",[408],"Osteoarthritis",{"date":341,"type":38},{"date":411,"type":38},"2022-09-01",{"date":345,"type":22},{"name":43,"class":44},{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":424,"conditions":425,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":427,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":431,"locationsCount":45},"100443617","combined-analysis-of-inflammatory-biomarkers-for-cns-autoimmune-diseases-diagnostic-100443617","NCT05056740","Combined Analysis of Inflammatory Biomarkers for CNS Autoimmune Diseases Diagnostic","Evaluation of a Combined Analysis of Serum and Cerebrospinal Fluid Inflammatory Biomarkers to Help in Etiological Diagnosis of Central Nervous System Autoimmune Diseases","CyBIRD","Inclusion Criteria:\n\n* Patients referred to our center for the diagnostic work-up of White Matter Lesions\n* Patients that need a routine blood analysis\n* Patients that need a routine CSF analysis\n* Non opposition to research consent\n\nExclusion Criteria:\n\n* Patients with a contraindication to perform spinal tap (increase bleeding risk medicine or disease)\n* Patients with a contraindication to MRI (metal prosthesis…)",{"count":423,"type":22},300,"Project rationale:\n\nSince 2017, multiple sclerosis diagnosis should match the new McDonald criteria in which a \"no better explanation than MS\" should be fulfilled. However, many patients present with red flags that lead to a complex diagnostic work-up. There are no available biomarkers that permit to confirm or roll out MS diagnosis in such cases. Therefore, we lack biological markers that can help in the diagnosis of patients presenting with suspected MS.\n\nMany studies have found that serum and cerebrospinal fluid (CSF) cytokines could help to differentiate MS from other diseases such as neuromyelitis optica spectrum disorders (i.e., IL-6) or neurosarcoidosis (i.e., sIL-2R). Serum and CSF kappa free light chains have also shown good diagnosis performance in MS. In daily practice, our MS tertiary center already perform the analysis of CSF concentrations of IL-1β, sIL-2R, IL-6, IL-10, and serum and CSF kappa and lambda free light chains to roll out other central nervous system (CNS) autoimmune diseases in patients presenting with white matter hyperintensities (WMH).\n\nObjective:\n\nTo correlate CSF IL-1β, sIL-2R, IL-6, IL-10, serum and CSF kappa and lambda free light chains with the final diagnosis in patients presenting to our MS tertiary center with suspected MS to identify a specific inflammatory biomarker profil involved in MS and other CNS autoimmune diseases.\n\nThe methodology:\n\nThis is an observational study. All patients ongoing a routine diagnostic work-up for suspected MS from june 2020 to june 2022 in our MS tertiary center will be analyzed. Cerebrospinal fluid IL-1β, sIL-2R, IL-6, IL-10, serum and CSF kappa and lambda free light chains will be correlated with the final diagnosis to ultimately find MS associated biomarkers.",[426],"Central Nervous System Diseases",{"date":321,"type":38},{"date":429,"type":38},"2020-06-01",{"date":345,"type":22},{"name":43,"class":44},{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":102,"sex":18,"minAge":440,"maxAge":4,"enrollmentInfo":441,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":442,"conditions":443,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":449,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":453,"locationsCount":45},"100433358","impact-of-auditory-stimulation-in-eating-pleasure-edere-2021-100433358","NCT04923087","Impact of Auditory Stimulation in Eating Pleasure (EDERE 2021)","Impact of Auditory Stimulation in Eating Pleasure : Multicentric Study With Biscuits With Crunchy Texture vs Soft Texture in 100 Seniors Affected or at Risk of Presbyacusis","EDERE 2021","Inclusion Criteria:\n\nSubjects 65 years of age or older, hospitalized in geriatrics or EHPAD residents.\n\nExclusion Criteria:\n\nrisk of false route when eating cookies, allergy to an ingredient in cookies","65 Years",{"count":335,"type":22},"Background. Decreased taste and smell contribute to loss of appetite (anorexia), and the resulting protein-energy malnutrition increases the frailty of the elderly. The risk of falls, disability, infections and depression often requires them to be institutionalized. Elderly, undernourished and toothless patients often complain about the monotony of a soft, mixed-texture diet. In a previous study, some participants highlighted the pleasure of crunching cookies that have a solid texture that can be eaten in any dental condition. However, the age-related decrease in hearing (presbyacusis) is frequent and progressive from the age of 60. The hypothesis of this work is that older patients may perceive a crunchy food crunching in their mouth, despite presbycusis. If the hypothesis is verified, this would make geriatric caregivers aware of the possibility of diversifying the texture of food, in order to stimulate the pleasure of eating and increase the dietary intake in this population of patients who are often undernourished, dysphagic, edentulous and hearing impaired. The originality of this study is to share the expertise of geriatricians and specialists in mastication\u002Fswallowing (dental surgeon, speech-language pathologist), hearing (ENT doctor, hearing care professional) and nutrition (dietician).\n\nType of study. Type of study MR-004 \"Research not involving the human person\". Protocol. Compare the noise and pleasure of crunching between two hyperprotein nutritional supplements: a soft filled cookie (Nutra Cake™, Délical, France) and a crunchy cookie of the Breton type (Protibis™, Solidages, France). Blind study impossible: each subject will eat a cookie then the other in a random order and will be his own control. The tests will be performed without the possible hearing aids, but with or without the dentures according to the patient's preference. Indeed, some patients have dental prostheses that are no longer suitable for chewing, and that they wear only for aesthetics. Objective. Validate the evaluation criteria \"Do you hear the biscuit crunch?\" and \"Is it a pleasure?\" If so, encourage diversification with crunchy foods with a suitable texture, as well as dental and prosthetic rehabilitation of dependent elderly people.",[444,445,446,447,448],"Frailty","Malnutrition","Anorexia","Presbycusis","Edentulism Nos",{"date":341,"type":38},{"date":451,"type":38},"2021-06-01",{"date":345,"type":22},{"name":43,"class":44},{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":460,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":462,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":463,"conditions":464,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":466,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":470,"locationsCount":45},"100397996","aicr--artificial-intelligence-in-cardiac-arrest-100397996","NCT04462380","AiCR : Artificial Intelligence in Cardiac aRrest","AiCR : Artificial Intelligence in Cardiac aRrest Application of an Algorithm in the Prognosis of Recovered Cardiorespiratory Arrests","AiCR","Inclusion Criteria:\n\n* OCA recovered from: hypoxic, ischemic, pulmonary embolism, tamponade, rhythm or conduction disorder, shockable or not, intra or extra-hospital.\n* CR computerized, typed in PDF format\n\nExclusion Criteria:\n\n\\-",{"count":105,"type":22},"The overall incidence of cardiorespiratory arrest in Europe is estimated at 350,000 to 700,000 cases per year. Survival rate is estimated at 10.7% for all rhythm disorders combined.\n\nSeveral examples of AI application in the medical field exist. Ting et al have developed a computer tool capable of diagnosing the presence of diabetic retinopathy with excellent power. In resuscitation, Celi et al proposed a tool capable of predicting the need for crystalloid vascular filling during a systemic inflammatory state. In Nature in 2018, Komorowski demonstrated the efficacy of AI in the hemodynamic management of sepsis. In a study of the renal response to fluid challenge, Zhang et al. demonstrate the effectiveness of the learning machine.\n\nObjectives: Determination of an algorithm capable of predicting the mortality of patients admitted to intensive care units (ICU) for ACR from hospitalization reports (CRH). Also use of the algorithm to predict the risk of recurrence of the arrest, the duration of mechanical ventilation, the appearance of sepsis, the development of organ failure, prediction of the CPC (Cerebral Performance Category), time to obtain catecholamine withdrawal, the appearance of acute renal failure with or without the need for extra-renal purification (EER) and duration under EER, the average length of stay.\n\nThis project is part of a larger, nationwide project with greater power, and includes all the data generated during hospitalization in intensive care.\n\nMethod: an estimated total number of patients included in this study to be between 300 and 500. The population will come from the intensive care units of Nice, Antibes, Cannes, Grasse.\n\nInclusion will be retrospective, on CRH, CR of CT imaging (cerebral and thoraco-abdomino-pelvic), MRI, EEG, and daily follow-up words, from 2014 to the end of 2020.\n\nAfter anonymisation, application of semantisation using natural language processing (NLP) methods. The data to be extracted are entered in a document written by intensive care physicians. These data will then be stored in a database. In order to meet the main objective, we will develop a computer algorithm capable of predicting mortality in the study population. This algorithm, based on a large database, can be designed using machine learning or even deep learning techniques depending on the amount of data to be processed.",[465],"Cardio Respiratory Arrest",{"date":341,"type":38},{"date":468,"type":38},"2020-02-01",{"date":345,"type":22},{"name":43,"class":44},{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":478,"minAge":19,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":480,"conditions":481,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":485,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":489,"locationsCount":45},"100392456","inflatable-penile-prostheses--which-patients-can-correctly-use-the-scrotal-pump--100392456","NCT04390230","Inflatable Penile Prostheses : Which Patients Can Correctly Use the Scrotal Pump ?","Inflatable Penile Prostheses : Predicting Factors of Pump Misuse and Unsatisfaction","All cases included were discussed and approved by a multidisciplinary team. Patients who underwent prosthesis replacement or second implantation were not included. We excluded patients who refused or were not able to answer our questionnaire, patients who provided unreliable answers, and patients that experimented a secondary malfunction of their IP.","MALE",{"count":132,"type":22},"Sexual health and satisfaction are well know as critical critera to assess quality of life, at any age. Among the multiple aspects of sexual health, erectile dysfunction (ED) is not anymore a fate, mainly thanks to the advent of phosphodiesterase type 5 (PDE5) inhibitors in 1998. Nevertheless, a significant part of patients are intolerant or does not respond to PDE5 inhibitors and thus are looking for other treatment options.\n\nSince the first implantation of foreign material intracarvernosally in 1966 by Beheri, multiple modifications and enhancements were achieved in order to produce devices more reliable with a more natural appearance. First introduced in 1973 by Scott et al., inflatable prosthesis provides now high general satisfaction rates (69-94%), better than in malleable prostheses, except for few authors.\n\nIn addition to changes in materials and construction, the two main manufacturers of IPP, Boston scientific AMS (Marlborough, MA, USA) and Coloplast (Minneapolis, MN, USA), modernized the pump mechanism of their devices. Since the introduction of AMS IPP, three main pump formats have been used : the standard pump has been replaced in 2004 by the \" Tactile \" pump and then the \" Momentary Squeeze \" (MS) pump in 2006, smaller and easier to deflate by not requiring the patient to hold the deflation button throughout deflation. Coloplast also replaced in 2008 their \" Genesis \" pump by a \" One Touch Release \" (OTR) pump, and finally in 2014 by the current \" Touch \" pump, smaller, and presenting a biconcave deflation button, easier to find.\n\nDespite all technological advances, appropriate pre-operative counselling and careful post-operative teachning, a significant part of patients has still difficulties to handle the pump and thus, does not use their IPP, regardless of any material malfunction. That situation obviously leads to patient's dissatisfaction and highlights the operating risks of a useless surgical procedure.\n\nThe purposes of this study were:to identify the risks factors, modifiable and non-modifiable, for patients' difficulty to inflate and\u002For deflate their device after IPP implantation, then to show a correlation between easy handling and post-operative satisfaction. And last but not least, to show an association between pre-operative pump pattern viewing and handling and post-operative easy handling. That information could help the physicians to improve the pre-operative selection of patients and to adapt the peri-operative care in order to improve patients satisfaction.",[482,483,484],"Surgery","Satisfaction","Penile Prosthesis; Complications",{"date":341,"type":38},{"date":487,"type":38},"2014-01-24",{"date":345,"type":22},{"name":43,"class":44},{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":496,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":203,"enrollmentInfo":498,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":499,"conditions":500,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":504,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":508,"locationsCount":45},"100388919","assessment-of-chilbains-occuring-during-covid-19-infection-100388919","NCT04344119","Assessment of Chilbains Occuring During Covid-19 Infection","Assessment of Skin Manifestations Occuring During Covid-19 Infection With a Special Focus on Chilbains","ChilblainCOVID","Inclusion Criteria:\n\n* All patients with proven covid infection (using PCR, serum antibody or lung TDM) and presenting at least one cutaneous lesions that occurred during the infection.",{"count":21,"type":22},"Some patients infected by covid-19 develop skin manifestations. These manifestations are still not well known and there pathophysiology remain unclear. Among them, acral manifestation resembling to chilblains appears frequent and quite specific. The aim of this project is to better characterize the cutaneous manifestations occurring during Covid-19 infection with a special focus on chilblains. These acral manifestation could be due to a direct viral effect, but also to microthrombosis or vascularitis. Understanding the pathomechanisms involved could provide interesting clue for understanding not only the skin manifestations but also some of the other systemic symptoms associated to covid-19 infection. This study plan to characterize these acral manifestations by analyzing the clinical and dermoscopic patterns and to correlate them with the non-invasive vascular explorations but also immune and coagulopathy explorations that are done in the CHU of Nice in covid-19 patients.",[501,502,503],"Skin Manifestations","COVID","Chilblains",{"date":341,"type":38},{"date":506,"type":38},"2020-04-09",{"date":345,"type":22},{"name":43,"class":44},{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":18,"minAge":180,"maxAge":516,"enrollmentInfo":517,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":519,"conditions":520,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":523,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":527,"locationsCount":45},"100354341","cutaneous-and-mucosal-manifestations-of-neurofribromatosis-type-2-in-children-under-15-100354341","NCT03893643","Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15","Multicentre Prospective Observational Study: Resentment of Mucocutaneous Manifestations and the Value of Dermatological Examination in the Early Detection of Type 2 Neurofibromatosis in Children Under 15 Years of Age","Inclusion Criteria:\n\n* age up to 15 years\n* diagnosis of neurofibromatosis type 2\n\nExclusion Criteria:\n\n* refusal to participate in the study\n* informed consent that can not be obtained because of a disability or difficulties with a - language barrier","15 Years",{"count":518,"type":22},1000,".Neurofibromatosis type 2 is an inherently autosomal dominant genetic disease, but cases of mosaicism or de novo mutation are not uncommon. the prevalence is estimated at 1 \u002F 60,000. the clinical presentation is based on the appearance of tumors in the central and peripheral nervous system. The current average age of diagnosis is around 25 to 30 years depending on the studies. Currently, the diagnostic criteria are based on the ENT, neurological and opthalmological manifestations of the disease. Cutaneous manifestations have been described in these patients. Except now, mucocutaneous manifestations of the disease are not taken into account for depisatage or diagnosis.\n\nThe purpose of this study would be to identify the different cutaneous and mucosal manifestations in a pediatric population under 15 years of age, and to analyze whether this might be of interest in early detection of the disease in association with other symptoms.",[521,522],"Neurofibromatosis 2","Dermatology\u002FSkin - Other",{"date":341,"type":38},{"date":525,"type":38},"2019-01-01",{"date":345,"type":22},{"name":43,"class":44},{"id":529,"slug":530,"hasResults":12,"nctId":531,"briefTitle":532,"officialTitle":532,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":534,"targetDuration":536,"studyType":206,"phases":4,"briefSummary":537,"conditions":538,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":540,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":544,"locationsCount":45},"100338713","nice-human-immunodeficiency-virus-hiv-cohort-100338713","NCT03690063","Nice Human Immunodeficiency Virus (HIV) Cohort","Inclusion Criteria:\n\n* Enrol consecutive patients with a scheduled visit in the outpatient clinic (regardless of CD4 cell count and ART status).\n\nExclusion Criteria:\n\n\\-",{"count":535,"type":22},2000,"3 Years","Historically, the database on the HIV was organized within the framework of the medico-economic file of the human immunodeficiency (DMI-2), introduced jointly by the Direction of Hospitals (Mission AIDS) and the INSERM at the end of the 80s. Today this database is fed via the computerized medical record NADIS. Most part of the research works on the theme of the HIV take support on this database (DAD, EuroAIDS, Neuradapt).",[539],"Human Immunodeficiency Virus",{"date":341,"type":38},{"date":542,"type":38},"1996-01-01",{"date":345,"type":22},{"name":43,"class":44},""]